Trial Profile

A Randomized Controlled Phase II Clinical Trial With Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tilsotolimod (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Acronyms Intrim 1 Study

Most Recent Events

17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
13 Sep 2022 Primary endpoint has been met (The rate of tumor positive sentinel lymph nodes (SLN)) , according to Results presented at the 47th European Society for Medical Oncology Congress
13 Sep 2022 Interim efficacy and safety results (n=108) presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com